International Stem Cell Corporation Blog: International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

Monday, June 13, 2011

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at www.internationalstemcell.com, or the PrecisionIR event site: www.vcall.com/CustomEvent/lipper/index.asp. An archived version will be available for 30 days.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation's Objectives

1. To create an abundant source of stem cells to meet the rapidly growing research and therapeutic demands of regenerative medicine.

2. To create stem cell lines from unfertilized eggs, which would have all the benefits of human embryonic stem cells, but are superior in their ability to eliminate or diminish immune rejection in the patient.

3. To create a methodology to “cross match” stem cells for transplant into individual patients and to build a true “Cell Bank” allowing for on-demand delivery of cells that could be matched to the patient’s own immune system and reduce or eliminate the need for immunosuppressant drugs.

Forward Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

-30-

Monday, June 13, 2011

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

ShareThis

Visit ISCO, LLCT and LLSC Websites

ISCO Mobile App QR

Subscribe here to have this info delivered to you

International Stem Cell Corporation Company Profile

International Stem Cell Corporation's Fan Box

Ben's Stem Cell News

Are You Pro Stem Cell Research?

Like this?

Check out the GEN Blog

Networked Blogs

We Blog Alot

ClickTale

ontoplist

hotvsnot

Add International Stem Cell Corporation news to your RSS reader

Subscribe, Visit or Listen to ISCO's New Podcast Below

Translate This Blog

Feed Shark

Blog Archive

International Stem Cell Corporation's Objectives

Forward Looking Statements